Abstract
Purpose
To examine the correlation between cell death and a common surrogate of death used in screening assays, we compared cell death responses to those obtained with the sulforhodamine B (SRB) cell protein–based “cytotoxicity” assay.
Method
With the SRB assay, the Hill equation was used to obtain an IC50 and final cell mass, or cell mass present at infinite agent concentrations, with eight adherent cell lines and four agents (32 agent/cell combinations). Cells were treated with high agent concentrations (well above the SRB IC50) and the death response determined as the time-dependent decrease in cells failing to bind both annexin V and vital fluorochromes by flow cytometry.
Results
Death kinetics were categorized as fast (5/32) (similar to the reference nonadherent Jurkat line), slow (17/32), or none (10/32), despite positive responses in the SRB assay in all cases. With slow cell death, a single exposure to a chemotherapeutic agent caused a slow, progressive increase in dead (necrotic) and dying (apoptotic) cells for at least 72 h.
Conclusions
Cell death (defined by annexin and/or fluorochrome binding) did not correlate with the standard SRB “cytotoxicity” assay. With the slow cell death response, a single exposure to an agent caused a slow conversion from vital to apoptotic and necrotic cells over at least 72 h (the longest time point examined). Here, increasing the time of exposure to agent concentrations modestly above the SRB IC50 provides a method of maximizing cell kill. If tumors respond similarly, sustained low doses of chemotherapeutic agents, rather than a log-kill, maximum tolerated dose strategy may be an optimal strategy of maximizing tumor cell death.
Similar content being viewed by others
References
Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113–1118
Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112–1116
Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27:897–900
Hirai T, Kawano K, Hirabayashi N, Nishiyama M, Yamashita Y, Mukaida H, Iwata T, Toge T (1991) A novel in vitro chemosensitivity test using materials collected by endoscopic biopsy. Anticancer Drugs 2:269–274
Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M et al (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276–5282
Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO (2009) Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA 106:16375–16380
Cohen A, Shirvan A, Levin G, Grimberg H, Reshef A, Ziv I (2009) From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res 19:625–637
Reshef A, Shirvan A, Shohami E, Grimberg H, Levin G, Cohen A, Trembovler V, Ziv I (2008) Targeting cell death in vivo in experimental traumatic brain injury by a novel molecular probe. J Neurotrauma 25:569–580
Fonge H, Chitneni SK, Lixin J, Vunckx K, Prinsen K, Nuyts J, Mortelmans L, Bormans G, Ni Y, Verbruggen A (2007) Necrosis avidity of (99m)Tc(CO)3-labeled pamoic acid derivatives: synthesis and preliminary biological evaluation in animal models of necrosis. Bioconjug Chem 18:1924–1934
Blankenberg FG (2009) Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V. Proc Am Thorac Soc 6:469–476
Garanger E, Hilderbrand SA, Blois JT, Sosnovik DE, Weissleder R, Josephson L (2009) A DNA-binding Gd chelate for the detection of cell death by MRI. Chem Commun (Camb) 29:4444–4446
Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Jaattela M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nunez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer G (2009) Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16:1093–1107
Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G (2009) Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 16:3–11
Guchelaar HJ, Vermes I, Koopmans RP, Reutelingsperger CP, Haanen C (1998) Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 42:77–83
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823
Voigt W (2005) Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110:39–48
Zubrod CG (1972) Chemical Control of Cancer. Proc Natl Acad Sci USA 69:1042–1044
Lee AC, Shedden K, Rosania GR, Crippen GM (2008) Data mining the NCI60 to predict generalized cytotoxicity. J Chem Inf Model 48:1379–1388
Fricker SP, Buckley RG (1996) Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. Anticancer Res 16:3755–3760
Jacobson BS, Ryan US (1982) Growth of endothelial and HeLa cells on a new multipurpose microcarrier that is positive, negative or collagen coated. Tissue Cell 14:69–83
Denoyer D, Perek N, Le Jeune N, Cornillon J, Dubois F (2005) Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines. Eur J Nucl Med Mol Imaging 32:820–827
Acknowledgments
Financial support: NIH R01’s EB004472 and EB009691 and by NIH P50CA086355.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blois, J., Smith, A. & Josephson, L. The slow cell death response when screening chemotherapeutic agents. Cancer Chemother Pharmacol 68, 795–803 (2011). https://doi.org/10.1007/s00280-010-1549-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-010-1549-9